News Sentiment

JANX sentiment intelligence

Janux Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.26 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-0.9% over one week, +14.3% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Avoiding Lag: Real-Time Signals in (JANX) Movement

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.9% Price digesting
Trend fit Trend active 14.3% over four weeks
Fair value -40.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 36
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 10
simplywall.st 8
TradingView 6
TradingKey 4
Stock Traders Daily 2
Simply Wall Street 2
Insider Monkey 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 18
Analyst action 7
Balance sheet 2
Deals and strategy 2
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (JANX) Movement

This article provides a real-time stock analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating near-term weak sentiment but mid-term strength within a broader long-term weak bias. It highlights specific resistance and support levels, along with three AI-generated trading

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 16:41
Source
Stock Traders Daily
Stock Titan Direct company coverage

Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings

Janux Therapeutics President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. This transaction, which occurred on July 8, 2026, increased his direct holdings to 388,582 common shares, while he sti

Tone
Positive 59/100
Event
Market update
Published
11 Jul 2026 05:39
Source
Stock Titan
Simply Wall Street Direct company coverage

Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth Indexes - What's Changed

Janux Therapeutics (JANX) shares rose 13.6% despite its recent removal from several Russell growth benchmarks, including the Russell 3000 and 2000. The article suggests this removal is a technical detail affecting liquidity and investor base rather than fundamental business chang

Tone
Negative 40/100
Event
Balance sheet
Published
09 Jul 2026 03:11
Source
Simply Wall Street
TradingView Direct company coverage

Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX

The article focuses on the "Price to sales forward" metric for Janux Therapeutics, Inc. (NASDAQ: JANX). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical analysis, and market data. The content is prima

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 03:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX

This article provides financial information for Janux Therapeutics, Inc. (NASDAQ: JANX) focusing on its price to earnings forward metric. The content highlights a specific period, its value, and the percentage change. It appears to be an excerpt from a financial data platform lik

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 21:39
Source
TradingView
www.marketscreener.com Direct company coverage

Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark

Janux Therapeutics, Inc. (JANX) has been removed from the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth benchmarks. This news follows a series of recent updates including leadership changes, analyst pric

Tone
Negative 32/100
Event
Analyst action
Published
29 Jun 2026 19:50
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark

Janux Therapeutics, Inc. (NasdaqGM: JANX) has been removed from the Russell 3000 Growth Benchmark, as well as the Russell 2500, Russell 2000, and Russell 3000E Growth Benchmarks. This news follows several other recent updates for the company, including leadership changes, adjuste

Tone
Negative 38/100
Event
Market update
Published
29 Jun 2026 15:09
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark

Janux Therapeutics, Inc. (NasdaqGM:JANX) has been removed from the Russell 2000 Growth Benchmark as of June 29, 2026. The biopharmaceutical company is currently developing tumor-activated immunotherapies for cancer, utilizing its TRACTr, TRACIr, and ARM bispecific platforms. This

Tone
Negative 31/100
Event
Market update
Published
29 Jun 2026 11:41
Source
marketscreener.com
Insider Monkey Direct company coverage

5 Most Promising Cancer Stocks According to Wall Street Analysts

This article identifies five promising cancer stocks according to Wall Street analysts, focusing on companies with significant price target upsides and pipeline developments. It highlights Janux Therapeutics, Inc. (NASDAQ:JANX) as one such company, detailing analyst ratings, its

Tone
Positive 66/100
Event
Analyst action
Published
28 Jun 2026 17:10
Source
Insider Monkey
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in JANX Response

Stock Traders Daily's Quantitative Research Desk has analyzed Janux Therapeutics Inc. (NASDAQ: JANX), identifying strong near and mid-term sentiment but a weak long-term outlook. The analysis highlights an exceptional risk-reward short setup targeting a 29.6% downside with minima

Tone
Neutral 50/100
Event
Guidance
Published
27 Jun 2026 07:40
Source
Stock Traders Daily
TradingView Direct company coverage

JANX Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Janux Therapeutics, Inc. (JANX) stock for 2027, based on analyst ratings and estimates. It includes current stock performance data, financial metrics like revenue and earnings, and answers frequently asked questions about the c

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:09
Source
TradingView
TradingView Direct company coverage

Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX)

This article provides an overview of Janux Therapeutics, Inc. (NASDAQ: JANX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for past quarters, and also provides upcoming ea

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:09
Source
TradingView
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX)

Healthcare analysts have issued bullish sentiments for Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX). Debanjana Chatterjee from JonesTrading reiterated a Buy rating for Sionna with a $63.00 price target, while Supawat Thongthip from Truist Financial gave Janu

Tone
Positive 87/100
Event
Analyst action
Published
26 Jun 2026 08:52
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions

Janux Therapeutics (JANX) is forecast to experience a decline in earnings at 16.8% per annum, while revenue is expected to grow by 47.7% annually. The company, which is currently unprofitable, has seen various price target changes and estimate revisions from analysts. Recent upda

Tone
Positive 64/100
Event
Earnings
Published
25 Jun 2026 13:41
Source
Simply Wall Street
Investing.com Australia Direct company coverage

Form 8K Janux Therapeutics Inc For: 23 June By Investing.com

This article announces that Janux Therapeutics Inc. filed a Form 8K for June 23. This is a brief notice from Investing.com, highlighting the company's regulatory filing. The notice includes their stock symbol JANX and its recent performance.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
24 Jun 2026 23:41
Source
Investing.com Australia
Stock Titan Direct company coverage

CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search

Janux Therapeutics announced the departure of its Chief Medical Officer, William Go, M.D., Ph.D., on June 23, 2026. The company stated his departure was a termination without "Cause" and does not reflect any disagreement over operations or strategy. Janux will begin a search for

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 19:40
Source
Stock Titan
TradingKey Direct company coverage

Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on Janux Therapeutics Inc. (JANX)'s revenue breakdown, but states that the relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It provides current stock information fo

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:11
Source
TradingKey
TradingKey Direct company coverage

Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Janux Therapeutics Inc. (JANX) regarding its dividends and stock splits. It states that the company has not distributed any dividends over the past five years and has no historical stock split data available. Financial data for JANX, including

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:11
Source
TradingKey
TradingKey Direct company coverage

Janux Therapeutics Inc (JANX) Institutional Confidence

Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 110.21%, showing a 0.64% increase quarter-over-quarter. Steven Cohen

Tone
Positive 60/100
Event
Market update
Published
16 Jun 2026 23:10
Source
TradingKey
TradingKey Direct company coverage

Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk

Janux Therapeutics Inc (JANX) has a risk assessment score of 2.93, ranking 175 out of 388 in the Biotechnology & Medical Research industry, with a beta of 2.54 indicating higher volatility than the S&P 500. The company's risk profile includes a 240-day maximum drawdown of +64.94%

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 23:09
Source
TradingKey
Stock Titan Direct company coverage

JANX SEC Filings - Janux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Janux Therapeutics (JANX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It highlights recent filings such as Janus Henderson's passive ownership report, Adage Capital's stake

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jun 2026 00:10
Source
Stock Titan
The Globe and Mail Direct company coverage

Janux Therapeutics Reports Results of 2026 Annual Meeting

Janux Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders elected two Class II directors, ratified Ernst & Young LLP as the independent accounting firm, and approved executive compensation. The company's stock, JANX, currently hold

Tone
Neutral 50/100
Event
Earnings
Published
14 Jun 2026 09:40
Source
The Globe and Mail
Stock Titan Direct company coverage

Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital

Janux Therapeutics director Jake Simson reported receiving 5,500 restricted stock units (RSUs) and options for 15,500 shares, with vesting tied to continuous service. These equity awards are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II, aligning

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 06:40
Source
Stock Titan
Stock Titan Direct company coverage

Janux Therapeutics (JANX) director awarded RSUs and stock options

Janux Therapeutics director Natasha Hernday received 5,500 restricted stock units (RSUs) and stock options for 15,500 shares. The RSUs vest by June 11, 2027, or the next annual stockholder meeting, while the stock options vest monthly over 12 months from June 11, 2026, both subje

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 06:40
Source
Stock Titan